Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease × alovudine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 10 Breast Neoplasms 8 Neoplasms 4 Head and Neck Neoplasms 4 Central Nervous System Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 2 Prostatic Neoplasms 2 Oligodendroglioma 2 Melanoma 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Glioma 2 Glioblastoma 2 Ependymoma 2 Carcinoma, Renal Cell 2 Astrocytoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Lymphoma 1 Lymphatic Metastasis 1

Interventions

Blood Specimen Collection 8 Surveys and Questionnaires 6 Magnetic Resonance Spectroscopy 6 Dexamethasone 6 Mammography 5 Cyclophosphamide 5 Colonoscopy 5 Biopsy 5 Prednisone 4 Positron Emission Tomography Computed Tomography 4 Magnetic Resonance Imaging 4 Lenalidomide 4 Biopsy, Fine-Needle 4 Tomography, X-Ray Computed 3 Surgical Procedures, Operative 3 Melphalan 3 Liquid Biopsy 3 Interviews as Topic 3 Diagnostic Tests, Routine 3 weifuchun 2 pembrolizumab 2 fluciclovine F-18 2 daratumumab 2 carfilzomib 2 Urination 2 Preoperative Exercise 2 Positron-Emission Tomography 2 Methods 2 Injections 2 Immunohistochemistry 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00633958 2021-10-20

FLT

Dana-Farber Cancer Institute

Phase 1 Terminated

Disease, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡